Public health. A case study of personalized medicine.
Katsanis
S H
SH
Genetics and Public Policy Center, Berman Institute of Bioethics [corrected], The Johns Hopkins University, Washington, DC 20036, USA.
Javitt
G
G
Hudson
K
K
D003577:Cytochrome P-450 Enzyme System / Q000235:genetics; D018795:Device Approval; D005820:Genetic Testing / Q000191:economics / Q000331:legislation & jurisprudence / Q000379:methods / Q000592:standards; D033161:Government Regulation; D006291:Health Policy; D006801:Humans; D040541:Marketing; D004364:Pharmaceutical Preparations / Q000008:administration & dosage; D010597:Pharmacogenetics; D011634:Public Health; D015203:Reproducibility of Results; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage; D014481:United States; D014485:United States Federal Trade Commission / Q000331:legislation & jurisprudence; D014486:United States Food and Drug Administration / Q000331:legislation & jurisprudence
D003577:Cytochrome P-450 Enzyme System; D004364:Pharmaceutical Preparations; D017367:Selective Serotonin Reuptake Inhibitors